Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLK2 | P49760 | 17/20 | 1.00 |
| ▸ | CLK3 | P49761 | 17/20 | 1.00 |
| ▸ | DYRK1A | Q13627 | 17/20 | 1.00 |
| ▸ | WNT1 | P04628 | 2/20 | 0.61 |
| ▸ | CDK7 | P50613 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18486888 | 0.92 | CLK2 (0.86) | CLK2CLK3DYRK1AWNT1 | |
| SCHEMBL20452012 | 0.92 | CLK2 (0.85) | CLK2CLK3DYRK1AWNT1 | |
| SCHEMBL18485093 | 0.91 | CLK2 (0.83) | CLK2CLK3DYRK1AWNT1 | |
| SCHEMBL20455243 | 0.90 | CLK2 (0.82) | CLK2CLK3DYRK1AWNT1 | |
| SCHEMBL18442108 | 0.90 | CLK2 (0.82) | CLK2CLK3DYRK1AWNT1CDK7 | |
| SCHEMBL18446810 | 0.90 | CLK3 (0.86) | CLK2CLK3DYRK1AWNT1CDK7 | |
| SCHEMBL18486997 | 0.90 | CLK3 (0.82) | CLK2CLK3DYRK1A | |
| SCHEMBL20454949 | 0.90 | CLK2 (0.82) | CLK2CLK3DYRK1AWNT1CDK7 | |
| SCHEMBL18485060 | 0.90 | CLK2 (0.81) | CLK2CLK3DYRK1AWNT1 | |
| SCHEMBL20422931 | 0.89 | CLK2 (0.81) | CLK2CLK3DYRK1AWNT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10463651-B2 | 3-(1H-pyrrolo[3,2-C]pyridin-2-YL)-1H-indazoles and therapeutic uses thereof | SAMUMED, LLC (US) | 2019-11-05 | — | — | US | claimed |
| US-20180221350-A1 | 3-(1H-PYRROLO[3,2-C]PYRIDIN-2-YL)-1H-INDAZOLES AND THERAPEUTIC USES THEREOF | VICKERS VENTURE FUND VI (PLAN) PTE. LTD. (SG) | 2018-08-09 | — | — | US | claimed |
| US-20230000842-A1 | METHODS OF TREATING CARTILAGE DISORDERS THROUGH INHIBITION OF CLK AND DYRK | VICKERS-SPLICE CO-INVESTMENT LLC (KY) | 2023-01-05 | — | — | US | disclosed |
| US-10463651-B2 | 3-(1H-pyrrolo[3,2-C]pyridin-2-YL)-1H-indazoles and therapeutic uses thereof | SAMUMED, LLC (US) | 2019-11-05 | — | — | US | disclosed |
| US-10463651-B2 | 3-(1H-pyrrolo[3,2-C]pyridin-2-YL)-1H-indazoles and therapeutic uses thereof | SAMUMED, LLC (US) | 2019-11-05 | — | — | US | disclosed |
| US-20180221350-A1 | 3-(1H-PYRROLO[3,2-C]PYRIDIN-2-YL)-1H-INDAZOLES AND THERAPEUTIC USES THEREOF | VICKERS VENTURE FUND VI (PLAN) PTE. LTD. (SG) | 2018-08-09 | — | — | US | disclosed |
| US-20180221350-A1 | 3-(1H-PYRROLO[3,2-C]PYRIDIN-2-YL)-1H-INDAZOLES AND THERAPEUTIC USES THEREOF | VICKERS VENTURE FUND VI (PLAN) PTE. LTD. (SG) | 2018-08-09 | — | — | US | disclosed |
| US-20180221350-A1 | 3-(1H-PYRROLO[3,2-C]PYRIDIN-2-YL)-1H-INDAZOLES AND THERAPEUTIC USES THEREOF | VICKERS VENTURE FUND VI (PLAN) PTE. LTD. (SG) | 2018-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10463651-B2 | 3-(1H-pyrrolo[3,2-C]pyridin-2-YL)-1H-indazoles and therapeutic uses thereof | WNT1, WNT3, WNT3A | CLK2 788/4885CLK3 683/4885DYRK1A 545/4885 |
| US-20180221350-A1 | 3-(1H-PYRROLO[3,2-C]PYRIDIN-2-YL)-1H-INDAZOLES AND THERAPEUTIC USES THEREOF | WNT1, WNT3, WNT3A | CLK2 788/4885CLK3 683/4885DYRK1A 545/4885 |
| US-20230000842-A1 | METHODS OF TREATING CARTILAGE DISORDERS THROUGH INHIBITION OF CLK AND DYRK | CLK2, CLK3, CLK1 | CLK2 1/4885CLK3 2/4885DYRK1A 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.